Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up
- PMID: 30429592
- PMCID: PMC6737527
- DOI: 10.1038/s41395-018-0396-x
Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up
Abstract
Background: There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.
Methods: A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).
Results: Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant).
Conclusions: For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.
Conflict of interest statement
CONFLICTS OF INTEREST
Figures
Comment in
-
Durability and Effectiveness of Cognitive-Behavioral Therapy for Irritable Bowel Syndrome.Gastroenterology. 2019 Dec;157(6):1684-1686. doi: 10.1053/j.gastro.2019.10.010. Epub 2019 Oct 12. Gastroenterology. 2019. PMID: 31614122 No abstract available.
Similar articles
-
Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.Gastroenterology. 2018 Jul;155(1):47-57. doi: 10.1053/j.gastro.2018.03.063. Epub 2018 Apr 25. Gastroenterology. 2018. PMID: 29702118 Free PMC article. Clinical Trial.
-
Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial.Lancet Gastroenterol Hepatol. 2019 Nov;4(11):863-872. doi: 10.1016/S2468-1253(19)30243-2. Epub 2019 Sep 3. Lancet Gastroenterol Hepatol. 2019. PMID: 31492643 Free PMC article. Clinical Trial.
-
Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.J Consult Clin Psychol. 2021 May;89(5):435-453. doi: 10.1037/ccp0000648. J Consult Clin Psychol. 2021. PMID: 34124927 Free PMC article.
-
Predictors of outcome in cognitive and behavioural interventions for irritable bowel syndrome. A meta-analysis.J Gastrointestin Liver Dis. 2018 Sep;27(3):257-263. doi: 10.15403/jgld.2014.1121.273.bab. J Gastrointestin Liver Dis. 2018. PMID: 30240469 Review.
-
Cognitive behaviour therapy for irritable bowel syndrome.Eur J Gastroenterol Hepatol. 2005 Jan;17(1):11-4. doi: 10.1097/00042737-200501000-00003. Eur J Gastroenterol Hepatol. 2005. PMID: 15647633 Review.
Cited by
-
The Role of Virtual Reality in the Management of Irritable Bowel Syndrome.Curr Gastroenterol Rep. 2024 Nov;26(11):294-303. doi: 10.1007/s11894-024-00940-w. Epub 2024 Aug 13. Curr Gastroenterol Rep. 2024. PMID: 39136889 Free PMC article. Review.
-
The Use of Psychotherapy for Refractory Irritable Bowel Syndrome: A Systematic Review.Cureus. 2024 Feb 13;16(2):e54138. doi: 10.7759/cureus.54138. eCollection 2024 Feb. Cureus. 2024. PMID: 38487115 Free PMC article. Review.
-
Factors That Predict Magnitude, Timing, and Persistence of Placebo-Like Response in Patients With Irritable Bowel Syndrome.Gastro Hep Adv. 2024;3(2):221-229. doi: 10.1016/j.gastha.2023.10.003. Epub 2023 Oct 14. Gastro Hep Adv. 2024. PMID: 38456188 Free PMC article.
-
Cognitive Behavioral Therapy for Chronic Pelvic Pain: What Is It and Does It Work?J Urol. 2024 Apr;211(4):539-550. doi: 10.1097/JU.0000000000003847. Epub 2024 Jan 16. J Urol. 2024. PMID: 38228093 Review.
-
Gut liver brain axis in diseases: the implications for therapeutic interventions.Signal Transduct Target Ther. 2023 Dec 6;8(1):443. doi: 10.1038/s41392-023-01673-4. Signal Transduct Target Ther. 2023. PMID: 38057297 Free PMC article. Review.
References
-
- Shah E, Kim S, Chong K, et al. Evaluation ofharm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125:381–93. - PubMed
-
- Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195–203. - PubMed
-
- Lackner JM, Keefer L, Jaccard J, et al. The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self-versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemp Clin Trials. 2012;33:1293–310. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
